About Pulmonary Fibrosis Efficacy Safety Expert View Mechanism of Action Dosage RA-ILD risk calculator Previous Next Read more Read more Previous Play Next Progressive Pulmonary Fibrosis: focus on autoimmune ILDs 16/02/2023 | Author: Boehringer Ingelheim Document ID: PC-SG-101833 EFFICACY A1-R101||A2-R101||INBUILD® Trial Efficacy (RA-ILD Subgroup Analysis) by Dr E. Volkmann FSIN||Progressive Pulmonary Fibrosis (PPF) - Diagnosis and Treatment in the ATS/ERS/JRS/ALAT Guideline SGOFV2023COM||INBUILD® Trial Efficacy (autoimmune ILD patients) SGOFV2023COM||INBUILD® Trial Population and Baseline Medications SGOFV2022COM||The key to managing progression in SSc-ILD patients Listen to our experts share their insights on why INBUILD® is an important study for patients with PF-ILD SGOFV2023COM||Largest prospective Phase III clinical trial in patients with SSc-ILD OFEV® across different disease severities OFEV® and acute IPF exacerbations OFEV® in IPF patients with FVC ≤50% predicted Progressive Pulmonary Fibrosis: Diagnosis & Treatment in the ATS/ERS/JRS/ALAT Guideline Progressive Pulmonary Fibrosis: focus on autoimmune ILDs Mortality data in IPF OFEV® is the first and only approved therapy for PF-ILD OFEV® reduces the risk of acute exacerbations as seen in INBUILD® RELATED CONTENT Read more 3:53 INBUILD® Trial Efficacy (RA-ILD Subgroup Analysis) by Dr E. Volkmann Watch now Opens in new tab Read more PDF FSIN||Progressive Pulmonary Fibrosis (PPF) - Diagnosis and Treatment in the ATS/ERS/JRS/ALAT Guideline Download Opens in new tab Read more PDF SGOFV2023COM||INBUILD® Trial Efficacy (autoimmune ILD patients) Download Opens in new tab Read more PDF SGOFV2023COM||INBUILD® Trial Population and Baseline Medications Download Opens in new tab Read more PDF SGOFV2022COM||The key to managing progression in SSc-ILD patients Download Opens in new tab Read more 2:33 Listen to our experts share their insights on why INBUILD® is an important study for patients with PF-ILD Watch now Opens in new tab Pagination Load more Home Inflammation Nintedanib EFFICACY Progressive Pulmonary Fibrosis: focus on autoimmune ILDs
Read more 3:53 INBUILD® Trial Efficacy (RA-ILD Subgroup Analysis) by Dr E. Volkmann Watch now Opens in new tab
Read more PDF FSIN||Progressive Pulmonary Fibrosis (PPF) - Diagnosis and Treatment in the ATS/ERS/JRS/ALAT Guideline Download Opens in new tab
Read more PDF SGOFV2023COM||INBUILD® Trial Efficacy (autoimmune ILD patients) Download Opens in new tab
Read more PDF SGOFV2023COM||INBUILD® Trial Population and Baseline Medications Download Opens in new tab
Read more PDF SGOFV2022COM||The key to managing progression in SSc-ILD patients Download Opens in new tab
Read more 2:33 Listen to our experts share their insights on why INBUILD® is an important study for patients with PF-ILD Watch now Opens in new tab